Isatuximab固定容量短时输注联合Pd治疗复发难治多发性骨髓瘤的1b期最终结果
这项1b期研究B部分评估了抗CD38单抗Isatuximab以250 mL固定容量输注联合泊马度胺和地塞米松(Pd)治疗复发难治多发性骨髓瘤的安全性和疗效。47例患者(中位既往治疗线数3线)接受治疗,总缓解率为53.2%,最常见的非血液学不良事件为乏力(63.8%)和输注反应(40.4%,均为2级且仅首次输注出现)。结果与A部分及III期ICARIA-MM研究一致,证实了固定容量输注的可行性。
要点
- 固定容量250 mL输注Isatuximab联合Pd的总体缓解率为53.2%(可评估人群55.5%,未接受过达雷妥尤单抗者60.0%)。
- 输注反应均为2级且仅发生于首次输注,中位首次输注时长3.7小时。
- 安全性和疗效与A部分及III期ICARIA-MM研究一致,支持固定容量输注的可行性。
核心结论
- 固定容量250 mL输注Isatuximab联合Pd在复发难治多发性骨髓瘤中显示出与既往输注方案一致的安全性、疗效和可行性。
研究设计与样本
- 1b期研究B部分(NCT02283775),纳入47例复发难治多发性骨髓瘤患者,中位既往治疗线数3线(范围1-8)。
- Isatuximab 10 mg/kg每周一次共4周、之后每两周一次,以250 mL固定容量(mL/h速率)输注,联合标准剂量Pd,28天为一周期。
主要发现
- 中位暴露时间36.9周,中位首次、第二次和第三次及以上输注时长分别为3.7、1.8和1.2小时。
- 最常见的非血液学治疗中出现的不良事件为乏力(63.8%),输注反应、咳嗽和上呼吸道感染各占40.4%。
- 输注反应均为2级,且仅发生于首次输注。
- 总缓解率在所有患者中为53.2%,在可评估人群中为55.5%,在未接受过达雷妥尤单抗的患者中为60.0%。
临床怎么用
- 固定容量250 mL输注Isatuximab联合Pd可作为复发难治多发性骨髓瘤的一种可行治疗选择,且输注反应仅见于首次输注。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Part B of this phase 1b study (ClinicalTrials.gov number, NCT02283775) evaluated safety and efficacy of a fixed-volume infusion of isatuximab, an anti-CD38 monoclonal antibody, in combination with pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma patients. Isatuximab (10 mg/kg weekly for 4 weeks, then every other week) was administered as a fixed-volume infusion of 250 mL (mL/h infusion rate) with standard doses of Pd on 28-day cycles. Patients (N = 47) had a median of three prior treatment lines (range, 1-8). Median duration of exposure was 36.9 weeks and median duration of first, second, and 3+ infusions were 3.7, 1.8, and 1.2 h, respectively. The most common non-hematologic treatment-emergent adverse events were fatigue (63.8%), infusion reactions (IRs), cough, and upper respiratory tract infection (40.4% each). IRs were all grade 2 and occurred only during the first infusion. The overall response rate was 53.2% in all patients (55.5% in response-evaluable population, 60.0% in daratumumab-naïve patients). Efficacy and safety findings were consistent with data from the isatuximab plus Pd infusion schedule in Part A of this study and also from the phase 3 ICARIA-MM study, and these new data confirm the safety, efficacy, and feasibility of fixed-volume infusion of isatuximab.
引用
- Usmani SZ, Karanes C, Bensinger WI, et al. Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma. Leukemia. 2021. PMID: 34050260. doi:10.1038/s41375-021-01262-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。